Cancer research in the 57 Organisation of Islamic Cooperation (OIC) countries, 2008-17.
Organisation of Islamic Cooperation
cancer anatomical sites
cancer research
citations
funding
research types
Journal
Ecancermedicalscience
ISSN: 1754-6605
Titre abrégé: Ecancermedicalscience
Pays: England
ID NLM: 101392236
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
07
2020
entrez:
5
10
2020
pubmed:
6
10
2020
medline:
6
10
2020
Statut:
epublish
Résumé
The 57 countries of the Organisation of Islamic Cooperation (OIC) are experiencing rapid increases in their burden of cancer. The First Ladies Against Cancer meeting at the 2016 OIC meeting in Istanbul committed to the importance of cancer control and the need for more evidence to support national cancer control planning (NCCP). Strong research systems are a crucial aspect of NCCP, but few data exist to support policy-makers across this political grouping. We identified all cancer research papers from OIC countries in the Web of Science from 2008 to 2017 with a filter based on journal names and title words, with high precision and recall. We analysed the country outputs, the cancer sites investigated, the types of research, sources of funding and the citations to the papers. There were 49,712 cancer research papers over this period. The leading countries in terms of output were Turkey, Iran, Egypt and Malaysia, but the most cited papers were from Qatar, Indonesia and Saudi Arabia. International collaboration was low, except in Qatar and the United Arab Emirates. The site-specific cancers accounting for most research were breast and blood, correlating with their disease burden in the OIC countries, but lung, cervical and oesophageal cancers were relatively under-researched. Most funding from within the OIC countries was from their own university sector. Cancer is seriously under-researched in most of the OIC countries. This will undermine the ability of these countries and OIC as a whole to deliver on better cancer control for their populations. New policies, OIC leadership and funding are urgently needed to address this situation.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
The 57 countries of the Organisation of Islamic Cooperation (OIC) are experiencing rapid increases in their burden of cancer. The First Ladies Against Cancer meeting at the 2016 OIC meeting in Istanbul committed to the importance of cancer control and the need for more evidence to support national cancer control planning (NCCP). Strong research systems are a crucial aspect of NCCP, but few data exist to support policy-makers across this political grouping.
METHODOLOGY
METHODS
We identified all cancer research papers from OIC countries in the Web of Science from 2008 to 2017 with a filter based on journal names and title words, with high precision and recall. We analysed the country outputs, the cancer sites investigated, the types of research, sources of funding and the citations to the papers.
RESULTS
RESULTS
There were 49,712 cancer research papers over this period. The leading countries in terms of output were Turkey, Iran, Egypt and Malaysia, but the most cited papers were from Qatar, Indonesia and Saudi Arabia. International collaboration was low, except in Qatar and the United Arab Emirates. The site-specific cancers accounting for most research were breast and blood, correlating with their disease burden in the OIC countries, but lung, cervical and oesophageal cancers were relatively under-researched. Most funding from within the OIC countries was from their own university sector.
CONCLUSION
CONCLUSIONS
Cancer is seriously under-researched in most of the OIC countries. This will undermine the ability of these countries and OIC as a whole to deliver on better cancer control for their populations. New policies, OIC leadership and funding are urgently needed to address this situation.
Identifiants
pubmed: 33014136
doi: 10.3332/ecancer.2020.1094
pii: can-14-1094
pmc: PMC7498278
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1094Informations de copyright
© the authors; licensee ecancermedicalscience.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Br J Psychiatry. 2007 Apr;190:314-8
pubmed: 17401037
Psychooncology. 2018 Sep;27(9):2172-2179
pubmed: 29856903
BMC Med. 2017 Jan 13;15(1):10
pubmed: 28081724
Eur J Cancer. 2018 Sep;100:75-84
pubmed: 30014883
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Lancet Oncol. 2020 May;21(5):637-644
pubmed: 32359488
Ecancermedicalscience. 2017 Apr 28;11:735
pubmed: 28596801
Global Health. 2016 Oct 12;12(1):63
pubmed: 27729081
JCO Glob Oncol. 2020 Feb;6:185-189
pubmed: 32023124
Eur J Cancer. 2018 Nov;104:127-136
pubmed: 30347288